Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa–Squamous Cell Carcinoma
- 15 October 2020
- journal article
- editorial
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 141 (4), 942-946
- https://doi.org/10.1016/j.jid.2020.08.022
Abstract
No abstract availableKeywords
Funding Information
- Epidermolysis Bullosa Medical Research Foundation
This publication has 14 references indexed in Scilit:
- Heterogeneous addiction to transforming growth factor‐beta signalling in recessive dystrophic epidermolysis bullosa‐associated cutaneous squamous cell carcinoma*British Journal of Dermatology, 2020
- STAT3 targeting in dystrophic epidermolysis bullosaBritish Journal of Dermatology, 2019
- Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa–Associated Squamous Cell CarcinomaClinical Cancer Research, 2019
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaThe New England Journal of Medicine, 2018
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)Journal of the American Academy of Dermatology, 2015
- Suppression of TGFβand Angiogenesis by Type VII Collagen in Cutaneous SCCJNCI Journal of the National Cancer Institute, 2015
- Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classificationJournal of the American Academy of Dermatology, 2014
- Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT studyClinical Pharmacology in Drug Development, 2014
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of MyelofibrosisClinical Cancer Research, 2012
- Epidermal differentiation and basement membrane formation by HaCaT cells in surface transplantsEuropean Journal of Cell Biology, 1998